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randomised controlled trial of the Strengthening
Families Programme 10–14 UK (SFP 10–14 UK)
Jeremy Segrott1*, David Gillespie2, Jo Holliday1, Ioan Humphreys3, Simon Murphy1, Ceri Phillips3, Hayley Reed1,
Heather Rothwell1, David Foxcroft4, Kerenza Hood2, Zoe Roberts5, Jonathan Scourfield6, Claire Thomas1
and Laurence Moore7Abstract
Background: Prevention of alcohol, drug and tobacco misuse by young people is a key public health priority.
There is a need to develop the evidence base through rigorous evaluations of innovative approaches to substance
misuse prevention. The Strengthening Families Programme 10–14 is a universal family-based alcohol, drugs and
tobacco prevention programme, which has achieved promising results in US trials, and which now requires
cross-cultural assessment. This paper therefore describes the protocol for a randomised controlled trial of the UK
version of the Strengthening Families Programme 10–14 (SFP 10–14 UK).
Methods/Design: The trial comprises a pragmatic cluster randomised controlled effectiveness trial with families as
the unit of randomisation, with embedded process and economic evaluations. Participating families will be
randomised to one of two treatment groups - usual care with full access to existing services (control group), or
usual care plus SFP 10–14 UK (intervention group). The trial has two primary outcomes - the number of occasions
that young people report having drunk alcohol in the last 30 days, and drunkenness during the last 30 days, both
dichotomised as ‘never’ and ‘1-2 times or more’. The main follow-up is at 2 years past baseline, and short-term and
intermediate outcomes are also measured at 9 and 15 months.
Discussion: The results from this trial will provide evidence on the effectiveness and cost-effectiveness of an
innovative universal family-based substance misuse prevention programme in a UK context.
Trial registration: Current Controlled Trials ISRCTN63550893.
Keywords: Substance misuse, Alcohol, Prevention, Strengthening Families Programme 10–14, SFP 10–14 UK,
Young peopleBackground
Risk behaviour by young people, including substance
misuse (alcohol, tobacco and illegal drugs), antisocial be-
haviour and crime has a substantial impact on the UK
economy and the health of its population. These behav-
iours are associated with morbidity and mortality among
young people, poor education, social exclusion, teenage
pregnancy, conduct disorders and poor health over the* Correspondence: segrottj@cardiff.ac.uk
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stated.life course [1-3]. The 2009/10 HBSC survey in Wales
indicated that at age 15, 50% of girls and 47% of boys re-
ported that they had been drunk twice or more (the
third highest of 38 countries); 16% of girls and 11% of
boys reported that they smoked cigarettes at least once a
week; and 20% of girls and 22% of boys reported that they
had ever used cannabis. Concerning drunkenness and
cannabis use prevalence, Wales, Scotland and England all
had rates above the HBSC average [4].
Intervention efforts have largely focussed on individual
risk behaviours, ignoring the co-occurrence of multiple
health risk behaviours [5]. In the 2012 survey of drug use,
smoking and drinking among 11–15 year olds in England,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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ing to 15% by age 15) [6]. Past week smoking was strongly
associated with other risk behaviours, and “[o]f the 6% of
pupils who reported smoking in the last week, most (5%
of all pupils) had also drunk alcohol or taken drugs re-
cently, or had done both” (p185).
The survey also found that truanting from school was
linked to these behaviours. For instance, “[p]upils who
had truanted from school were more likely to be regular
smokers compared with pupils who had never truanted
(odds ratio = 2.02)” (p36).
Understanding the co-occurrence of multiple health
risk behaviours and their association with poor educa-
tional outcomes, social disadvantage, conduct disorders
and poor physical and emotional health is therefore an
important area of current public health research [5,7-10].
Similarly, there is increased interest in prevention efforts
which focus on risk and protective factors such as pro-
social behaviour, resilience and positive youth develop-
ment [11-13], and which therefore have the potential to
impact upon multiple risk outcomes. Family-based risk
and protective factors have been identified as important
targets for intervention [14], including the modelling of
parents’ alcohol use [15], rules and monitoring around
substance use [16,17], and more general parenting styles
and relationships within families [18-20]. Parenting and
family interventions form a central part of many govern-
ments’ health, welfare and education policies, and preven-
tion of substance misuse is also a key priority [21-25]. Yet
interventions are often developed without reference to the
existing evidence base or theoretical frameworks, and im-
plemented without rigorous evaluation [26].
A promising programme which has targeted multiple
risk behaviours by addressing risk and protective factors
located in the family is the Strengthening Families
Programme 10–14 (SFP 10–14). It draws on theories of
bio-psychosocial vulnerability, resiliency and family process,
and was initially developed as the 14-session Strengthening
Families Programme for high-risk families with children
aged 6–12 years whose parents were misusing alcohol or
drugs. The revised SFP 10–14 is a seven week universal
programme targeting young people aged 10 to 14 years and
their parents [27]. SFP 10–14 has been reported to be
effective over a six-year follow-up period in promoting
family integration, delaying the onset of alcohol use, re-
ducing uptake of smoking, the incidence of harder drug
use (methamphetamine) [28-31] and substance use at
10 year follow-up (aged 21) [32]. Delaying the age of
initiation of substance use is an important goal, since
epidemiological research has indicated that later onset
of alcohol and drug use is associated with reduced life-
time prevalence of alcohol and drug problems [33-35].
US-based cost-benefit assessments indicate that SFP
10–14 can be cost-effective at the population level forpreventing alcohol misuse, other alcohol problems and
also for tobacco use [36-38], cannabis and other drug
use prevention. A potential ten-fold return for every dol-
lar invested in the programme has been reported [36],
although the authors conclude that economic analysis
had largely been unexplored in the evaluation of such in-
terventions. Another US study that examined the SFP
10–14 alongside other school-based programmes has
shown that the costs of participation amounted to US
$150 while the benefits realised could be as much as US
$1000 per participant, depending on the extent of drug
use [38]. The emphasis in these studies has been on the
cost-benefit ratio and whether prevention can generate
returns on investment from avoidance of other costs in
other sectors and in future years. The results of such
studies are highly dependent on the perspective taken
and the nature and range of assumptions made. Most
critically, they are dependent on the existence of high
quality investigations that utilise reliable and valid out-
come measures to produce indications of effect and that
yield detailed and relevant cost information from a range
of perspectives. Well conducted studies of this nature
can contribute to subsequent meta-analyses and model-
ling exercises to identify efficient policy options.
The current evidence base for SFP 10–14 is derived
exclusively from the US from two trials conducted by
the same research team. Recent Cochrane systematic re-
views and a 2006 technical report to the World Health
Organisation (WHO) Expert Committee on Problems Re-
lated to Alcohol Consumption recommend that the SFP
10–14 is adapted and tested in other cultures and set-
tings before widespread implementation [39,40]. Recent
methodological critiques of the two existing RCTs of
SFP 10–14 point to limitations in the statistical analyses
by the original research team, namely the use of multiple
and one sided statistical tests leading to claims of statis-
tical significance at p < 0.05 that may not be justified
[41-45]. In these critiques the key issue is statistical preci-
sion, and an intention-to-treat re-analysis of the original
data for a Cochrane review highlighted that the results of
the SFP 10–14 trials showed an important effect with low
precision [39]. For example, in this re-analysis the Abso-
lute Risk Reduction and 95% confidence interval for
drunkenness was 11.27% (0.31% to 22.24%). This under-
lines the need for additional, high quality trials to assess
effectiveness and cost-effectiveness with precision and
determine whether the programme has long-term public
health benefits. This view is reinforced by a recent inde-
pendent UK Department of Health-commissioned review
of prevention and behaviour change in young people,
which concluded that “More RCTs [are needed] of the
Strengthening Families Program” [46].
It is not clear whether the apparent effectiveness of
the SFP 10–14 in reducing alcohol and drug problems at
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United States, will translate to other cultures, settings
and countries. The SFP 10–14 has recently been culturally
adapted for use in the UK [47,48] and there is substantial
UK policy interest in the programme. This includes the
use of the SFP 10–14 as part of the UK Government’s
Family Intervention Projects across a small number of se-
lected sites in England, which target high risk families
[49]. An evaluation of the programme’s implementation in
Barnsley, England (which mainly used the original US
programme materials), highlighted the need for some
cultural adaptation (now completed) and consideration of
the best approach with regards to universal or high-risk
targeting [50,51]. Many studies have highlighted the
challenges associated with targeted programmes for
young people, including recruitment, stigmatisation,
and managing group dynamics, with the potential for
harmful peer modelling effects [52-58]. Such targeting
also risks losing the beneficial group effects which are
achieved through the universal delivery of programmes
such as SFP 10–14 to whole school populations, as in
the US SFP10-14. In Cardiff, Wales, UK, these problems
led to the development of an innovative approach of
providing the SFP 10–14 as a universal intervention
(available to any family via practitioner referral or family
application), and running mixed groups of families from
the ‘general population’ in combination with families
with challenges (in the context of a group setting) [59],
with the aim of promoting positive group dynamics.
Groups of families attending the SFP therefore normally
comprise around 70% from the general population, and
30% who may experience or present challenges in a
group setting (families with challenges). It should be
noted that in this ‘mixed families’ approach, such chal-
lenges relate specifically to the delivery and receipt of
the group sessions, rather than general characteristics of
participants’ support needs, family functioning or other
risk factors. Examples of the challenges experienced or
presented by families therefore include issues such as
low literacy levels, behavioural problems (e.g. anger/ag-
gression) and exclusion of children from school (and
who may find working in a group setting challenging).
An earlier paper describes the mixed families approach
in more detail [59]. These mixed groups demonstrated
evidence of high levels of participant retention and ac-
ceptability, and social effects outside the programme,
with participating families supporting each other be-
tween sessions and after the end of the programme. Our
trial of the SFP 10–14 UK in Wales (Project SFP Cymru)
uses this ‘mixed families’ approach to group recruitment
and composition, as well as the fully culturally adapted
materials. The trial therefore builds on the completed for-
mative evaluation, adaptation and exploratory evaluation
of the UK version of the programme [47,48,50,51,59], andwill generate important new evidence on the programme’s
long-term effectiveness and cost-effectiveness in the UK.Methods/design
Study design
The trial comprises a pragmatic cluster randomised
controlled effectiveness trial with families as the unit of
randomisation, with embedded process and economic
evaluations.Recruitment
SFP 10–14 UK will be implemented in seven geographical
areas of Wales by local agencies that are independent of
the research team (e.g. local authority parenting teams,
children’s charities). Trial areas will run the programme
on approximately 8 occasions over a two year period, with
a maximum capacity of 10–12 intervention families per
programme.
SFP 10–14 UK is designed for delivery to families with
children aged 10–14, and in the Wales adaptation is tar-
geted towards a mix of children and their families. Each
programme is open to families from a loosely defined and
fairly large geographical area. In each area, self-referrals to
the Programme come forward in response to awareness-
raising in community and educational settings. Other re-
ferrals come from agencies such as education, health and
social services which identify families that may benefit
from participating in the Programme.
Potential referrers and families are informed that the
Programme is being run as part of a trial and are provided
with brief information about the trial. When a family is re-
ferred or applies to the SFP 10–14 they will be visited by a
member of the programme delivery team (normally the
programme coordinator) who will undertake a needs and
eligibility assessment. Based on the information contained
in the family referral/application form and the needs and
eligibility assessment the coordinator determines if eligible
families are from the ‘general population’ or a family with
challenges (in the context of a group setting). If families
are deemed eligible to attend the programme they will be
asked if they are willing for a member of the research
team to have access to their referral notes and to visit
them. Where the family agrees a research fieldworker will
then visit them to obtain informed consent to participate
in the trial, collect baseline data using a computer assisted
personal interview (CAPI), and inform the family of the
treatment group (C or I) to which they have been rando-
mised. Figure 1 shows the anticipated flow of participants
through the trial.
We will offer all parents and young people who pro-
vide data at 2 year follow-up a £10 gift voucher. All
adults who take part in the 9 and/or 15 month inter-
views will be entered in to a prize draw with the chance
Figure 1 Participant flow diagram.
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Participants
Inclusion and exclusion criteria
Table 1 describes the trial’s inclusion and exclusion cri-
teria. Any families deemed eligible to attend SFP 10–14
UK will be included in the research trial, subject to their
giving consent. Only families agreeing to participate in
the trial and randomised to receive the intervention will
have access to SFP 10–14 UK.
Ethical approval
Ethical approval for the trial was given by the Research
Ethics Committee for Wales (reference 09/MRE09/53).
Informed consent
Prior to being visited by a research fieldworker, all fam-
ilies who are invited to participate in the research trial
will be mailed an information sheet. This will include
specific documents for parents/carers and young people.
There will also be information for parents/carers about
our request to involve their children in the trial. The field-
worker will go through this information with families and
address any queries or concerns that they may have.
Informed consent will be obtained from all partici-
pants. For a family to be included in the research trial at
least one parent/carer must consent to participate, and
parent/carer consent for the inclusion of at least one
young person in the trial is required. Young people will
also need to give consent for their participation in the
research trial. The fieldworker will be careful not to
offer, or in any way imply access to the programme.
Randomisation
Families agreeing to participate in the research trial and
who provide baseline data will be randomised using aTable 1 Trial inclusion and exclusion criteria
Inclusion criteria
At least one parent/carer and one child are willing to attend the
programme together
The ability to speak English (help can be provided for parents or
children with low literacy levels). Some programmes may also be
delivered through the medium of Welsh if there is sufficient demand
A programme is being offered at a location to which it is practicable for
a family to travel (as determined by the programme coordinator) within
the next three months
Families with a child aged 10-14
-
-computerised randomisation facility that will randomise
families within strata defined by area (7) and use mini-
misation on the following variables:
 the category to which the family have been assigned
(general population/family with challenges);
 age of children wishing to attend the programme
(<12/12+). A mean will be taken if there is more
than one child; and
 the number of children in the family wishing to
attend the programme (1/>1).
There will be complete concealment of the randomisa-
tion sequence, set up securely within the randomisation
database by the statistician, from the field recruitment staff
and other trial team members. A random element, set at
80%, will also be used to increase the integrity and reduce
the deterministic nature of the randomisation process.
Intervention
Participating families will be randomised to one of two
treatment groups. Either they will receive usual care with
full access to existing services and a minimal information
leaflet (control group-C), or they will receive the SFP 10–
14 UK programme in addition to usual care with full
access to existing services (intervention group – I). There
will not be a defined programme of usual care, and the
existing variation in services available to participants
across the participating areas will continue throughout the
trial period.
SFP 10–14 is open to families from a loosely defined
and fairly large geographical area. The ‘mixed families’
approach aims to recruit about 4 families with chal-
lenges per group, and 6–8 families from the ‘general
population’. Self-referrals (applications by families) come
forward from awareness-raising in community and edu-
cational settings. Families are therefore drawn from theExclusion criteria
Situations where either a parent or child does not want to attend the
programme
Parents or children who cannot speak English (or Welsh, where
appropriate)
No programme is being offered at a location to which it is practicable
for a family to travel (as determined by the programme coordinator)
within the next three months. In such a case the family would not be
excluded. They will be placed on a waiting list for the programme and
will be contacted when a programme is available. They will then be
recruited into the trial
-
Families who do not live together - e.g. the child/children are in care
Families with very high needs or challenges (such as serious substance
misuse problems, family breakdown or crisis)
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and at the end of the programme, but are not normally
from a small or defined community such as a school or
local neighbourhood. The programme comprises seven
weekly sessions of two hours and is delivered in a range
of community venues by a multi-agency team of trained
professionals. In each session there is an hour during
which parent sessions and young people sessions are
conducted separately, followed by a second combined
family hour. Typically the first hour focuses on skills (e.
g. peer resistance for the young people, parenting for the
parents), with the second hour designed to enable par-
ents and young people to focus on communication skills,
recognise family strengths, and practice skills covered in
the first hour [27].
Objectives
The trial’s primary objective is to assess the effectiveness
of the SFP 10–14 UK in preventing alcohol misuse in
young people. Its secondary objectives are to assess the
programme’s impact on drug misuse, smoking behaviour,
alcohol initiation and drink-related problems and school
performance, among young people. Tertiary objectives
are to measure the extent to which SFP 10–14 UK has
effects on mental health and wellbeing, and protective
factors for alcohol and tobacco use/misuse located in
the family (e.g. family functioning, parenting and young
people’s peer resistance skills). The trial will measure the
costs associated with programme delivery and whether it
is cost effective. It will assess if there are important vari-
ations in delivery and receipt across trial sites, and iden-
tify key programme theory, content and processes.
Outcome measures
The trial has two primary outcomes - the number of
occasions that young people report having drunk alcohol
in the last 30 days; and drunkenness during the last 30
days, dichotomised as ‘never’ and ‘1-2 times or more’.
Secondary outcomes (mainly concerned with long-term
alcohol/tobacco/substance behaviours) are: reported use
of cannabis (ever vs. never); weekly smoking (yes vs no,
validated by salivary cotinine measures); age of alcohol
use initiation; frequency of drinking more than 5 drinks
in a row in the last 30 days; frequency of different types
of alcoholic drinks; alcohol-related problems; and General
Certificate of Secondary Education (GCSE) performance at
age 15/16 (number of GCSEs passed and grades achieved,
measured as a continuous outcome). All primary and sec-
ondary outcomes are collected from children at 2 year
follow-up, with the exception of GCSE results, which we
propose to collect via the Secure Anonymised Information
Linkage (SAIL) Databank [60], once all participants have
completed GCSEs/left compulsory education. The trial’s
tertiary outcomes (mainly concerned with health andfamily wellbeing, and also substance use initiation) are:
parenting (General Child Management Scale child report);
family functioning (Family Relationship Index); children’s
wellbeing and stress (Strengths and Difficulties Question-
naire scores); children’s health status (SF-36); parents/
carers’ health status (GHQ and EQ5D); indicators of rela-
tive cost-effectiveness (derived from the health data); chil-
dren’s smoking status (i.e. whether they have ever smoked/
smoke now); young people’s self-efficacy; age of first
cigarette; and age of first drug use. Tables 2, 3, 4, 5, and
6 provide a description of the trial’s primary, secondary
and tertiary outcomes, and the specific measures used
in each of the data collections. Selection of outcomes at
9, 15 and 24 months was informed by a literature review
undertaken as part of the process evaluation.
Assessments and data collection
Baseline
Computer assisted personal interviews (CAPIs) are con-
ducted by research fieldworkers with parents/carers and
children. Children’s baseline CAPIs cover: substance use
behaviours, and aggressive and destructive behaviour;
strengths and difficulties (using the Strengths and Diffi-
culties Questionnaire); health, and sleeping patterns. Five
sets of questions assess aspects of participants’ home life,
namely: possessions the participants have in their bed-
room; family activities and free time activities; family
functioning; and parenting/child management. Full de-
tails are provided in Table 2.
Parent/carer interviews cover: drug and tobacco use,
and parental reports of children’s substance use; parent–
child bonding; parenting and family relationships and ac-
tivities: and parents/carers’ health status. Participants also
complete the parent version of the Strengths and Difficul-
ties Questionnaire (SDQ). Table 3 provides a full list of
questions and measures included in the interviews.
Follow-up
9 and 15 months
Parents/carers are followed up at 9, and 15 months past
baseline, using computer aided telephone interviews
(CATIs) conducted by the Participant Resource Centre
at Cardiff University. Interviews at 9 and 15 months
(Table 4) are identical, and collect data on hypothesised
short term and intermediate outcomes. Baseline mea-
sures of parent–child bonding and parenting/child man-
agement are repeated. Parental expectations of their
child(ren) and opportunities for the latter to participate
in household tasks are assessed. Health, criminal justice
and social care services utilisation is captured.
24 months
At two years past baseline CAPIs are conducted by
research fieldworkers with parents/carers and children
Table 2 Measures collected at baseline from young people
Domain/question topic Purpose Measure/source
Personal information
Gender, school year, age, DOB, place of birth, ethnicity
and cohabitants
DE Adapted from general household survey [61]
Family affluence DE Family affluence scale [62,63]
Substance use
Ever smoked? CV One question from substance initiation index [29]
Smoking status CV ASSIST study version of NatCen/NFER question [64]
Ever drunk a drink? CV NatCen/NFER [65]
Age of first drink? CV NatCen/NFER [65]
Frequency of drinking CV NatCen/NFER [65]
Ever little drunk? CV Adapted from HBSC questionnaire
Little drunk in last 3 months? CV Adapted from HBSC questionnaire
Ever really drunk? CV Adapted from HBSC questionnaire
Really drunk in last 3 months? CV Adapted from HBSC questionnaire
Ever taken drugs CV Adapted from HBSC / NatCen/NFER
Behaviour
Strengths and difficulties CV SDQ [66]
Aggressive and destructive conduct CV From Spoth, et al. [28]
Life at home
Things in your bedroom CV Adapted from young people, new media survey [67,68]
TV, computer games, computer use CV From HBSC questionnaire
Free time activities CV Modified questions from west of Scotland twenty-07 study
Family functioning CV Family relationship index [69,70]
Parenting/child management CV General child management, project family [71,72]
Parents and school CV Three questions, one of which is adapted from the
child rearing practices measure
Family activities CV From HBSC questionnaire/PEACH study
General health
Sleep – difficulties CV From HBSC questionnaire
Getting up/bedtimes CV From PEACH study
Health state today CV, HE EQ-5D [73]
General health CV Kidscreen 27 [74]
Key: CV = Covariate; HE = Health Economics; DE = Demographics; IO = Immediate outcome; ST = Short term outcome; PO = Primary outcome; SO = Secondary
outcome; TO = Tertiary outcome.
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ticipants’ substance use, health status and health and social
care service utilisation. Young people’s interviews repeat
baseline measures of smoking, alcohol and drug use. Add-
itional questions examine age of first cigarette, age of first
drunkenness, last month drinking frequency (including
types of drinks), binge drinking and drunkenness fre-
quency, cannabis use, and alcohol-related problems. The
interview also assesses child reports of short term/inter-
mediate outcomes, opportunities for involvement in pro-
social activities in participants’ families, and attachment to
parents, parenting/child management, and parental in-
volvement in school work/activities. The extent to whichyoung people help around the home is captured using suit-
ably adapted versions of the questions asked to parents at
9/15 months. Other questions assess self-efficacy, school
bonding, and interaction with anti-social peers. The child
version of the SDQ is also administered. Measures of par-
ticipants’ health used at baseline are repeated. Saliva sam-
ples are collected from consenting young people to assess
inhalation of tobacco smoke in the previous few days,
using a cotton wool swab of a salivette [88].
Sample size
We will aim to recruit 378 families in each arm of the
trial (756 families in total). This will provide us with at
Table 3 Measures collected at baseline from parents/carers
Domain/question topic Purpose Source
Personal information
Place of birth, relationship status, ethnicity, qualifications, DE Adapted from general household survey [61]
Employment DE NS-SEC
Co-habitants DE Adapted from GHS [61]
Substance use
Smoke (Y/N) CV
Cigarettes smoked per day CV Heaviness of smoking index [75]
Frequency of drinking CV Adapted from AUDIT-C [76]
Number of drinks consumed when drinking CV Adapted from AUDIT-C [76]
Frequency of drinking 6+ drinks in a row CV Adapted from AUDIT-C [76]
Ever used drugs CV Adapted from HBSC/NatCen/NFER [65]
Child’s substance use
Has child ever smoked? CV Question adapted from substance initiation index [29]
Does child smoke now? CV Adapted from NatCen/NFER [65]
Has child ever had a drink? CV Adapted from NatCen/NFER [65]
Has child ever been drunk? CV Developed by project SFP Cymru research team
Has child ever used drugs? CV Adapted from HBSC/NatCen/NFER [65]
Strengths and difficulties
Strengths and difficulties CV SDQ [66]
Section 6
Free time – use of TV, computer, etc. CV From HBSC questionnaire
Family activities CV From HBSC/11-16 West of Scotland adult questionnaire
Family functioning CV Family relationship index [69,70]
Parenting/child management CV General child management measure, project family [71,72,77]
Parent–child bonding CV Adapted from Spoth’s rural urban cumulative risk index and
Arthur, et al. [78,79]
Parents and school CV Questions developed by project team and one from Conger’s
child rearing practices measure
Measures of health status
Health status HE GHQ-12 [80,81]
Health HE 1 item from SF-36 [82]
Health state today HE EQ-5D [73]
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for our two primary outcomes) to detect either a 12%
difference in young people reporting having drunk al-
cohol (assuming a control group prevalence of 48%
[4]), or a 10% difference in young people reporting hav-
ing been drunk (assuming a prevalence of 22% [4]), at
two year follow-up. This sample size is based on an
average family in the trial having 1.25 young people, an
intracluster correlation coefficient (ICC) of 0.2 and is
adjusted to allow for 25% loss to follow-up (including
withdrawals from the trial by participants prior to 24
month follow-up).Analysis
Main analysis
The primary analyses will be based on the intention-to-
treat principle and will involve fitting two-level logistic
regression models to our primary outcomes (reported
drinking at two year follow-up and reported drunken-
ness at two-year follow-up), with responses from young
people nested within families. The covariates in the
models include those balanced at randomisation (type of
family – general population/family with challenges, and
average age of young people) and baseline levels of
drinking and drunkenness (depending on the outcome).
Table 4 Measures collected at 9 and 15 month follow-up
from parents/carers
Domain/question
topic
Purpose Source
Life at home
Parenting/child
management
IO General child management
measure, project family [71,72,77]
Parent–child bonding ST Adapted from Spoth’s rural urban
cumulative risk index and Arthur,
et al. [78,79]
Parents and school ST Questions developed by project team
and one from Conger’s child rearing
practices measure
Parental expectations IO Adapted from ALSPAC study/
developed by project SFP Cymru
research team
Participation in
household tasks
IO Adapted from ALSPAC/developed
by project SFP Cymru research team
Service utilisation
Health service
utilisation
HE Adapted from ALSPAC
Social care for adults HE Adapted from ALSPAC
Social care for
children
HE Adapted from ALSPAC
Criminal justice HE Adapted from ALSPAC
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tion) will be adjusted for. For each primary outcome, a
statistically significant result will be concluded if the
p-value for the trial arm explanatory variable is <0.025.
While our power calculation is based on the above, a
combined test will be performed if both p-values lie be-
tween 0.025 and 0.05. This will take the correlation of
the outcomes into account and provide an overall p-
value for the two outcomes.
The primary analyses will also be repeated
 controlling for any baseline imbalances;
 without controlling for any of the above mentioned
covariates;
 respecting the original ordinal scale (the primary
questions are asked on an ordinal scale ranging from
0 occasions to 40+ occasions) using an ordinal
regression model; and
 using a complier average causal effect (CACE)
approach, to investigate the treatment effect in the
treatment adherent.
Secondary analysis includes investigating the effect of
the intervention on substance use (reported use of to-
bacco and cannabis) at two year follow-up by fitting two-
level logistic regression models, controlling for baseline
reports of substance use, as well as the variables balanced
at randomisation (all models will control for the variables
that were balanced on at randomisation). The effect of theintervention on the proportion of young people reporting
alcohol-related problems will be analysed similarly. The
effect of the intervention on substance initiation (alcohol,
tobacco and cannabis) will be investigated by fitting two-
level Cox proportional hazards models (young people
nested within families) for those participants who had not
already initiated at baseline.
Educational achievement at 16 will be compared be-
tween trial arms by fitting a two-level logistic regression
model (young people nested within families) comparing
the proportion of young people who obtain five or more
GCSEs at a grade C or above (GCSE Grades use an A*-
G scale, with A* being the highest score). The propor-
tion of young people who continue in education beyond
16 will be similarly compared between trial arms by fit-
ting a logistic regression model. This analysis will be
performed on the whole sample following the date that
all participants (young people) should have completed
school Year 11 when GCSEs are normally awarded. Other
secondary and tertiary outcomes (e.g. parenting and child
management, parent–child affective behaviour and well-
being and stress) will be analysed by fitting similar regres-
sion models, controlling for clustering of responses within
families (as appropriate) and controlling for variables that
were balanced on at randomisation.
Sub-group & interim analysis
There is no planned interim analysis. Exploratory sub-
group analyses are planned for:
 age of young person at baseline;
 gender of young person;
 smoking behaviour of young person at baseline;
 parental drinking behaviour at baseline;
 socio-economic status (using both the Family
Affluence Scale and occupational status, which will
be analysed separately);
 family status (general population/with challenges); and
 trial area.
Up to two subgroup analyses will be performed to test
hypotheses generated from the process evaluation. These
will be specified in a later version of the Statistical Ana-
lysis Plan (SAP) before any trial analysis takes place, and
will be generated by researchers with no access to the trial
outcome data. Subgroup analyses will also be performed
to assess differential treatment effects for those who may
be at high risk of substance initiation and misuse (based
on baseline scores for SDQ, the Family Relationship Index
and the General Child Management Scale).
Process evaluation
An embedded process evaluation is examining how the
programme is implemented and will facilitate interpretation
Table 5 Measures collected at 24 month follow-up from young people
Domain/question topic Purpose Measure/source
Behaviour - strengths and difficulties
Strengths and difficulties/wellbeing and stress TO SDQ [66]
Life at home
Family activities (opportunities for involvement in
pro-social activities; possibly bonding)
ST From HBSC/PEACH study
Young people’s own time From west of Scotland Twenty 07
Parenting/child management IO/ General child management measure, project family
[71,72,77]
TO
Parents and school Three questions; one adapted from the child rearing
practices measure
Help around the home IO Adapted versions of questions asked to parents at
9/15 months.
Development of self-efficacy ST/ TO Bandura’s self efficacy scale [83]
Attachment to parents ST The security scale [84]
Befriending pro-social/anti-social peers ST Social development model scale on friends’ anti-social
qualities (Interaction with antisocial peers scale) [85]
Positive bonding to school ST School bonding measure/SDM [86]
Participant substance use
Smoking behaviour – ever smoked? Question from substance initiation index [29]
Smoking status TO/ SO ASSIST study version of NatCen/NFER question [64]
Age first smoked TO From HBSC questionnaire
Ever drunk a drink? NatCen/NFER [65]
Age of first drink SO Adapted from HBSC/NatCen/NFER
Drinking frequency, last month (including different types) SO Adapted questions from HBSC questionnaire
Ever really drunk? From HBSC questionnaire
Age first drunk Adapted version of question in HBSC questionnaire
Number of times drunk, drinking alcohol or 5+ drinks in
a row in last month
PO/SO Adapted from HBSC questionnaire
Alcohol-related problems SO Q21 from ESPAD survey [87]
Drug use – ever used? Amended from HBSC/NatCen/NFER [65]
Cannabis use (ever, 12 months, or 30 days) SO From HBSC questionnaire
Age of first drug use TO Adapted from HBSC questionnaire
General health
Health state today HE/TO EQ-5D (child version) [73]
General health HE/TO UK Kidscreen 10 [74]
Segrott et al. BMC Public Health 2014, 14:49 Page 10 of 21
http://www.biomedcentral.com/1471-2458/14/49of outcome effects [89]. In line with MRC’s guidelines [90],
this component of the trial will enable the development
and refinement of a programme logic model of the SFP10-
14 UK by the research team, including its key processes,
impacts and outcomes. The process evaluation has two key
research questions: (1) How is the SFP 10–14 UK thought
to influence social and individual behaviour of family mem-
bers so that young people are less likely to use tobacco,
misuse alcohol or to demonstrate other kinds of antisocial
behaviour?; and (2) What are the best ways of implement-
ing SFP 10–14 UK, and is there important variation indelivery and receipt? Following the framework proposed by
Linnan and Steckler [91], the process evaluation will exam-
ine four key issues: trial implementation and context; trial
arm fidelity; participation, reach and dose received/deliv-
ered; and reception and responsiveness. The process evalu-
ation has the following aims, namely to:
 identify key programme content and processes;
 assess trial arm implementation and context;
 evaluate fidelity and completeness of programme
delivery;
Table 6 Measures collected at 24 month follow-up from
parents/carers
Domain/question topic Purpose Source
Section 2 – consent
Life at home
Family activities From HBSC/11-16 West of
Scotland adult questionnaire
Family functioning TO Family relationship index
[69,70]
Parenting/child
management
IO General child management
measure, project family
[71,72,77]SO
Parent–child bonding ST Adapted from Spoth’s rural
urban cumulative risk index
and Arthur, et al. [78,79]
Parents and school Question developed by
project team and one from
Conger’s child rearing
practices measure
Participant substance use
Smoking behaviour Heaviness of smoking index
[75]
Alcohol use Adapted AUDIT-C questions, as
used by Pre-empt study [76]
Drug use Adapted from HBSC/NatCen/
NFER [65]
Health
Health status HE GHQ [80,81]
TO
Health HE 1 item from SF-36 [82]
Health state today HE EQ-5D [73]
TO
Service utilisation
Health, social care, education
and criminal justice service
utilisation
HE Modified from ALSPAC
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 calculate the extent of families’ attendance at SFP
10–14 UK sessions; and
 evaluate reception and response by families.
Multiple sources of evidence will be used to answer
the research questions. Data collection will comprise:
 interviews with Welsh Government staff involved in
programme commissioning (n = 1) and SFP training
staff (n = 2), programme coordinators (n = 6), and
coordinator managers (n = 6). Apart from
coordinator managers, all these participants will be
asked to take part in two interviews – once during
the early period of programme delivery, and again
towards the end; six focus groups (one in each delivery site) with staff
involved in programme delivery (n = 48-60);
 completion of reflection sheets by facilitators after
each session (n ≤ 336) to assess fidelity of delivery;
 researcher observation of programme sessions (three
in each area, spread across the evaluation period).
Two facilitators’ meetings (used to review and plan
programme delivery) will be observed in each
area; and
 8–10 intervention group families will be invited to
take part in focus groups in each area. Separate
groups will be conducted with young people and
parents/carers from the same families. Parents/carers
from 8–10 control group families will also be invited
to take part in a focus group in each area; and
 collection of routine data on programme
recruitment, staffing and retention.
Table 7 shows how each of the data collection methods
maps on to the aims and objectives.
Process evaluation analysis
Qualitative data from the process evaluation will be sub-
jected to a thematic content analysis [92]. Key themes will
be developed into an analytical framework. Each interview
transcript will be entered into Atlas.ti 6, which will be
used as a data management tool, permitting data coded to
the same theme to be accessed quickly for further analysis.
Each transcript will be coded to indicate the programme
delivery location and type of participant, allowing analyt-
ical themes to be explored in relation to different groups’
experiences and to compare implementation across the
seven areas and trial arms. Quantitative data on fidelity,
participation and dose will be used in secondary analysis
of outcome effects.
Health economic evaluation
Aim
The aim of the economic evaluation is to assess the costs
and effects associated with SFP 10–14 UK from the per-
spective of the UK Treasury - encompassing health and
social services, education and criminal justice, and partici-
pating families, in a cost-consequences analysis. The cost-
consequences analysis provides a comparative analysis of
the alternative programmes available to participants (usual
service provision only versus SFP 10–14 UK plus access to
usual service provision) and a clear descriptive summary
of the costs of SFP 10–14 UK and the consequences (out-
comes for participants, service utilization, and utility
gains). Effects will be reported separately enabling a full
evaluation of the different outcome components (main
trial outcomes, service utilisation, and utility gains) and re-
lated to the costs for both of the trial arms. Further, dis-
tinction will be made between the costs incurred in the
Table 7 Process evaluation aims, objectives and methods
Aim Objectives Literature
review
Interview
with Welsh
government
staff
Interviews
with
programme
trainers
Interview
with
coordinators
and managers
Focus
groups with
programme
facilitators
Facilitator
reflection
sheets
Observation of
programme
sessions and
facilitator
meetings
Focus groups
with
intervention
group
families
Focus
groups
with
control
group
parents
Routine
data
Main
trial
data
Inform decisions
regarding which
proximal outcomes
should be captured at
9, 15 and 24 month
follow-up interviews
with parents/carers;
To develop a
theoretical model of
the SFP10-14 UK, spe-
cifying the social and
behavioural hypoth-
eses that underlie the
programme.
✓
To use the theoretical
model to predict
proximal outcomes.
Identify key
programme content
and processes;
To link proximal
outcomes to
components of
implementation.
✓ ✓ ✓ ✓ ✓
To compare scores for
measures of
hypothesised
proximal and long-
term outcomes from
questionnaire respon-
dents in intervention
and control groups.
To revise and develop
the logic model to
take account of
further hypotheses
and priorities
suggested by the
data.
To determine how
and when key aspects
of delivery should be
measured in order to
assess fidelity to
programme aims
Assess trial arm
implementation and
context;
To describe
implementation of
the SFP10-14 UK, in-
cluding characteristics
of implementing
agencies, staffing
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
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Table 7 Process evaluation aims, objectives and methods (Continued)
arrangements, referral
routes and integration
of services.
To identify barriers
and facilitators to
implementation.
To identify family
support services other
than SFP10-14 UK
used in trial areas.
Evaluate fidelity and
completeness of
programme delivery;
For each area and
programme run, to
assess how closely
implementation of
SFP10-14 UK sessions
matches the design
and aims of SFP10-14
UK described in the
programme manual
✓ ✓ ✓ ✓ ✓ ✓ ✓
To describe planned
and actual roll out of
SFP10-14 UK in each
area.
To identify key factors
influencing adherence
To estimate
consistency in the
provision of normal
services
Assess participation
and reach;
In the intervention
arm, to estimate the
number of
participants by
different demographic
groups, i.e. by gender;
by age of children; by
number of adults and
children attending
from each family; and
by biological/other
relationship of
parents/carers to
young people.
✓ ✓
In both trial arms, to
estimate the number
of study participants
using family support
services other than
SFP10-14 UK, by
demographic groups.
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Table 7 Process evaluation aims, objectives and methods (Continued)
Calculate the extent
of families’
attendance at SFP10-
14 UK sessions
To collate and
summarise data
showing (i) how
many sessions are
attended by each
family; (ii) what
proportion of the
total number of
enrolled family
members attends
each SFP10-14 UK
session.
✓ ✓ ✓
Evaluate reception
and response by
families
To explore parents/
carers’ and young
people’s experiences
of attending the SFP
and other services in
terms of acceptability,
their opinion of their
value to them as
individuals and any
barriers or facilitators
to participation.
✓ ✓ ✓ ✓
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in each trial area (programme delivery site), so as to assess
variation and potential for efficiency gains, if ‘lowest costs’
and ‘best outcomes’ were achieved across the board.
Methods
Costs will be categorised according to whether they are
research or programme related, with discussions held
with relevant staff to agree the attribution factors used
to determine costs of SFP 10–14 UK. Further, the agen-
cies that incur costs will be clearly specified, as will the
agencies that benefit from reductions in resource util-
isation, so as to enable inter-sectoral comparisons to be
undertaken.
Based on service utilisation data collected from adult
trial participants at 9, 15 and 24 month follow-up, all
inputs and services provided by agencies will be docu-
mented in descriptive terms and wherever possible trans-
lated into monetary terms using appropriate published
unit cost data (e.g. BNF [93], PSSRU [94], NHS Reference
Costs [95]). A series of cost modules will be developed, to
establish a profile of costs relating to the agency that in-
curred them. Overall costs of providing SFP 10–14 will be
computed and will include programme set up costs, and
costs of implementing and delivering the programme.
The cost per participant and cost per family of attending
SFP 10–14 UK will be computed for the trial and for
each programme area. The costs of setting up SFP 10–
14 UK will include promotional materials and resources
involved in participant recruitment, in particular the
number of hours spent promoting/raising awareness of
the programme.
The costs of implementing and delivering SFP 10–14
UK will include staff time, venue and equipment costs,
provision of support facilities, materials utilised etc. Par-
ticipation in SFP 10–14 UK is likely to result in changes in
the utilisation of other services provided by a range of
agencies. These will be captured within the trial so as to
identify the extent of costs offset as a result of the
programme, and which represent one aspect of the out-
comes generated by the programme. This will be done by
collecting data on service utilisation from participants
(and changes over time) at 9, 15 and 24 month follow-up.
The combination of changes in service utilisation over
time and costs of SFP 10–14 UK delivery will result in a
net cost per participating family, which will be used in
the assessment of the relative cost-effectiveness of the
programme. The extent to which these changes in ser-
vice utilisation are likely to be sustained over time will
be modelled and quantified to produce scenarios for
assessing the longer term efficiency of the programme.
Information regarding the number of participants re-
quiring childcare support and transport to attend SFP
10–14 UK, and details of the job title and employer ofprogramme staff who deliver each programme will be
accessed from a monthly data return proforma submit-
ted by each programme delivery team. Most data on the
cost of delivering SFP 10–14 will be accessed via financial
monitoring forms, submitted to the research team by the
agencies with responsibility for leading programme delivery
in each trial site. These forms capture all costs incurred by
programme delivery teams, including those relating to spe-
cific SFP programmes (e.g. venue hire, refreshments, pay-
ment of participant travel expenses, provision of childcare
for younger siblings taking part in the programme). As
most programme facilitators are employed by a network of
partner agencies (not the agency with primary responsibil-
ity for implementation), the associated staffing costs may
not be available. If actual salary costs of facilitators cannot
be obtained they will be derived from the hours worked
documented on the Financial Monitoring Form and
matched to the job title and employer information gath-
ered via the Monthly Data Form. The salary associated
with professional grade of each facilitator will be derived
from relevant PSSRU unit cost data and multiplied by
the hours worked to derive an estimate of staffing costs
for facilitators. Where members of the research trial
team organise or contribute to promotional events (e.g.
information stands at school parents’ evenings) the
costs incurred will be captured using a ‘Record of costs:
promotional events' proforma. The provision of services
other than SFP 10–14 UK to trial participants will be
measured as part of 9, 15 and 24 month follow-up inter-
views with parents/carers. Table 8 provides a summary
of cost categories and data sources and measures.
Health economic analysis
Effects The differences in primary, secondary and ter-
tiary outcomes will represent the consequences of SFP
10–14 UK programme delivery to be used in conducting
the cost consequences analysis. As part of this process
the responses to EQ5D, collected from adults at baseline
and 24 month follow-up, will be used to generate QALYs
gained as a result of SFP 10–14 UK and compute the
cost/QALY ratio.
Cost-consequences analysis The cost consequences will
be assessed once all necessary data has been collected,
and post-trial modelling will be employed to assess the
cost consequences over longer time horizons than is
possible within the trial period. Changes in resources
utilised over time will be calculated and used in conjunc-
tion with the costs of setting up and delivering SFP 10–
14 UK to generate the overall cost of programme
delivery per family, which will represent the incremental
cost of providing the programme relative to usual ser-
vice provision. The differences in primary, secondary
and tertiary outcomes (including differences in utility
Table 8 Summary of cost categories and data sources and measures
Cost category Data source/measure
SFP implementation costs
Staff (including any recruitment/training costs) Financial monitoring forms + PSSRU (2012)
Venue and equipment Financial monitoring forms
Programme materials Financial monitoring forms
Venue hire Financial monitoring forms
Transport (for participants) Financial monitoring forms
Refreshments Financial monitoring forms
Childcare costs Financial monitoring forms
Costs of any trips/pamper days arranged for families at the end of the programme Financial monitoring forms
Participant service resource utilisation (Unit costs)
GP surgery visit (Per patient contact lasting 11.7 minutes) PSSRU (2012)
GP telephone consultation (Per telephone consultation lasting 7.1 minutes) PSSRU (2012)
GP home visit (Per out of surgery visit lasting 23.4 minutes) PSSRU (2012)
Community nurse - Home Visit (District nursing sister, District nurse) PSSRU (2012)
Outpatient attendance NHS reference Costs 2012
Inpatient attendance NHS reference Costs 2012
Substance misuse services Various + PSSRU (2012)
Mental health services Various + PSSRU (2012)
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up) will be used alongside the net cost of programme
delivery in the cost consequences analysis to generate a
set of indicators of relative cost-effectiveness within the
trial period, based on incremental cost and incremental
outcomes. Missing data will be dealt with by employing
an appropriate imputation-based method for effective-
ness and quality of life data [96], while the usual method
for dealing with censored data relating to costs will be to
employ the weighted cost method with known cost his-
tories [97].
Sensitivity analysis
A series of one-way sensitivity analyses will be under-
taken to assess the extent to which changes in the
variables affect the baseline estimates. The variables will
be adjusted in line with emerging distributions of data
values, and impact on baseline estimates computed. A
threshold analysis will also be undertaken to determine
the degree of parameter variation required to alter con-
clusions derived from baseline findings. A series of sce-
narios will be developed and utilised within an economic
model to assess the relative efficiency of SFP 10–14 UK
over longer time horizons. Probabilistic sensitivity analysis
will be undertaken to produce cost-effectiveness accept-
ability curves to assess the probability that SFP 10–14 UK
represents value for money. Future costs and benefits will
be discounted at the prevailing rate (currently 3.5% pa) to
bring into present values. Costs and benefits will be dis-
counted at 0% and 6% in the sensitivity analysis.Modelling The evaluation will also include a post-trial
modelling phase, using a decision-analytic model, which
will reflect longer time horizons than those available
from within the trial period. The model will be popu-
lated with relevant information from within the trial
period, but will also create a series of scenarios that re-
flect longer term costs and outcomes, based on param-
eter variation and discussion with experts.
Public involvement
The MRC guidance on complex interventions recom-
mends that “appropriate users should be involved at all
stages of the development, process and outcome analysis
of a complex intervention, as this is likely to result in
better, more relevant science and a higher chance of pro-
ducing implementable data” (p59) [90]. The involvement
of the public has also been advocated in research policies
to ensure that research is relevant, reliable and under-
standable [98,99]. Project SFP Cymru sits within the
DECIPHer research centre which employs an Involving
Young People Research Officer (IYPRO). This officer
will be responsible for advising how public involvement
is conducted throughout the trial.
All trial participants will be invited at baseline inter-
view to be part of stakeholder groups. Parents and young
people who consent will be contacted about the stake-
holder events in their area. The frequency and content
of the stakeholder events will vary dependent on the
stage of the research and the need for lay input. It is
envisioned that lay members will be consulted on trial
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newsletter, and identifying approaches to disseminating
the findings of the trial to a lay audience, although flexi-
bility will be built into the stakeholder events so that in-
dividuals can raise other issues they think are important
for the research. The use of both top-down and bottom-
up mechanisms of public involvement is designed to
create a meaningful involvement process for all research
participants. As recommended by INVOLVE, a national
advisory organisation that aims to increase public involve-
ment in NHS, public health and social care research,
all lay members’ expenses will be covered, including
travel and childcare costs, and vouchers will be given
to compensate for time contributed [100]. We will also
establish a stakeholders group to which all SFP coordi-
nators will be invited, in order to promote effective
communication between the research team and local
practitioners.
Discussion
Substance misuse is an important public health chal-
lenge and is associated with a range of short-term and
long term harms. Positive family relationships and aspects
of parenting (such as consistency, emotional warmth and
monitoring) have been identified as key protective factors
against young people’s misuse of alcohol, drugs and to-
bacco [101]. Prevention interventions which promote these
protective factors therefore have the potential to make a
significant impact on the health and wellbeing of young
people. Such potential impacts cannot be assumed, and so-
cial interventions, like their clinical counterparts, may be
ineffective in achieving their long term goals, or have
unintended or sometimes harmful effects [54,102,103].
Prevention interventions therefore need to be theoretically
grounded in their development, and subjected to rigorous
evaluation before decisions about widespread imple-
mentation are made. This trial will assess the long-term
effectiveness of the recently adapted UK version of the
Strengthening Families Programme 10–14, including its
impact on rates of alcohol consumption and drunken-
ness in young people aged 12–16 in a UK context. It
seeks to understand how and why any identified out-
comes occur, and to inform the future development of
the programme in the UK.
Whilst parenting and family interventions are a key
focus of UK social and public health policy, the majority
of the interventions in this area have been developed in
the United States [104-106]. It cannot be assumed that
the effectiveness of an intervention in the country it is
developed in will be replicated in new settings, or that
programme logic models will operate in identical ways
across different cultural contexts. Prevention interven-
tions which are transported to new countries may re-
quire adaptation (which needs to balance fidelity withcultural relevance), and should be subject to rigorous
evaluation to assess their effectiveness, and how key
programme change processes function in new settings
[107]. The results from this trial will help inform future
decisions about the implementation of SFP 10-14 in the
UK, and will demonstrate if the effectiveness of the
programme in the US is replicated in a UK context using
culturally adapted materials. It therefore contributes to
parallel research endeavours on SFP 10-14 in a number
of other countries [108-110].
As well as assessing the impact of the culturally adapted
SFP 10-14 in the UK on long-term outcomes, the current
trial is evaluating the implementation model developed in
and being employed in Wales. A core aspect of this model
is the strategy of retaining the SFP 10–14 as a universal
prevention intervention (accessible to any family in a local
community), and of forming programme groups to com-
prise a mix of families from the general population, and
those who may experience/present challenges in a group
setting. This model seeks to avoid some of the harmful ef-
fects of targeted interventions, including anti-social peer
contagion [58]. Relatively few previous studies of parent-
ing/family-based prevention programmes have examined
strategies to enhance group dynamics, implementation
fidelity or family engagement through group composition
strategies [59]. Our process evaluation will allow us to
understand whether the programme was delivered as
intended (including the composition of SFP groups), what
factors influenced this, and relationships between quality/
adherence of programme delivery and outcomes (at a trial,
area and family level). By embedding process and eco-
nomic evaluations within the main trial we therefore aim
to contribute to current knowledge about the value of uni-
versal prevention interventions, and the challenges of
implementing family-based programmes.
In this trial we also aim to address some of the key
methodological critiques of previous randomised con-
trolled trials of the SFP10-14, particularly those concern-
ing the use of multiple statistical tests, and the absence
of a pre-specified primary outcome [41-43]. A key chal-
lenge when evaluating complex interventions such as
SFP 10-14 is that they are designed to impact on mul-
tiple long-term health behaviours through enhancing
manifold protective factors (parenting style, family com-
munication processes, young people’s life skills), making
the traditional trial design of a single primary outcome
and small number of secondary outcomes inappropriate
[90]. Thus we have specified two primary outcomes (re-
lated to drinking frequency and drunkenness frequency),
alongside secondary and tertiary outcomes, and this is a
strength of the trial design. The outcome measures map
onto, and are designed to test a logic model for the
programme developed by the research team, which has
also driven the selection of short-term and intermediate
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overall effectiveness of the SFP10-14, and its predicted
causal pathways.
In order to maximise the external validity and utility of
our findings we have adopted a pragmatic effectiveness
trial design [111,112], in which recruitment procedures
and delivery systems replicate ‘real world’ implementation.
Thus in our trial of SFP 10–14 UK the programme is pro-
vided by local agencies that are likely to implement it in
the future, and the research team does not seek to impose
inclusion criteria with the aim of reducing the heterogen-
eity of the trial population (as might happen in an ex-
planatory trial which attempts to recruit homogenous
groups of participants). Participating families therefore
comprise children from across the 10–14 age band which
the programme is aimed at (12–16 at follow-up), and it is
possible that the SFP10-14’s potential impact on health
behaviours such as alcohol could be patterned according
to age.
The trial team will need to obtain support from local
agencies delivering SFP 10–14 for the trial, many of
whom may have little or no previous experience of run-
ning parenting/family/substance misuse prevention pro-
grammes as part of an RCT. Practitioners (and others)
may object to random allocation on the grounds that
they believe that the intervention is likely to be effective
[113], and that participants have unmet needs which
SFP 10–14 UK addresses. Whilst central to many practi-
tioners’ concerns may be the sense that participants ran-
domised to the control condition are ‘given nothing’
(what Wong, et al. describe as ‘resentful demoralisation’
in the context of no treatment control groups) [114], in
pragmatic trials such as ours, both intervention and con-
trol group families continue to receive ‘care as usual’ (i.e.
whatever services or programmes are usually available),
though usual care/services may differ across trial sites.
One potential response of practitioners to allocation of
participants to a control group is to offer a compensa-
tory package of treatment or support [115], which can
undermine the equivalence of the two arms of a trial. It
will also be important for us to avoid contamination of
the control group, and therefore ensure that families al-
located to the control group are not offered SFP 10–14
UK prior to their 24 month follow-up interviews. We
aim to build strong relationships with agencies involved
in referring families to, and delivering SFP 10–14 through
embedding research staff within these agencies, organising
presentations to explain the rationale for the RCT design
(and the need to maintain intervention and control groups
and equivalence of access to usual care), and engaging the
support of influential individuals (such as senior managers
and team leaders). We have also sought to build strong
partnerships with key policy makers, with the aim of gen-
erating high level support for the trial, and also increasingthe likelihood that the results can be translated into policy
and practice. In common with other comparable trials
[116-118], we are likely to experience challenges with
recruitment and retention of families. We plan to use a
number of strategies to retain young people and par-
ents/carers in the trial, including regular communica-
tion with participants, using agencies and schools to
reach families who may have moved house after baseline
data collection, forming groups of trial participants to ad-
vise us on the acceptability and likely impact of potential
approaches, and offering incentives (e.g. vouchers, prize
draws) at follow-up.
In conclusion, this trial aims to evaluate a promising
family-based substance misuse prevention programme fol-
lowing its adaptation for the UK. The trial is designed to
assess the effectiveness of SFP 10-14 UK, the extent to
which it is delivered as intended (and key influences), and
the costs and consequences of the programme. We aim to
examine the relationship between trial outcomes and fidel-
ity of implementation, and the value of the group compos-
ition strategies being used by SFP 10–14 UK practitioners
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